Clinical trial

Study of Enzalutamide (Formerly MDV3100) as a Neoadjuvant Therapy for Patients Undergoing Prostatectomy for Localized Prostate Cancer

NCT01547299

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2012-03-31

PhasePHASE2

Study timeline

Study start (actual)2012-03-31Date precision: day

Registry last updated2018-10-23

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Prostate Cancerunresolved

Interventions

EnzalutamideDRUG · verified · RxNorm: enzalutamide

LeuprolideDRUG · verified · RxNorm: leuprolide

DutasterideDRUG · verified · RxNorm: dutasteride

Sponsors & collaborators

Pfizerlead sponsor

Astellas Pharma Inccollaborator

Medivation LLC, a wholly owned subsidiary of Pfizer Inc.collaborator

Mapped research locations

BostonMassachusetts, United States1 TorontoOntario, Canada1 SeattleWashington, United States1 VancouverBritish Columbia, Canada1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01547299 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.